Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)
Inclusion Criteria:
- Female patient, >/= 18 years of age
- Metastatic breast cancer
- 1st-line treatment with Herceptin initiated in 2002
- Included in pharmaco-epidemiologic HERMINE study
Exclusion Criteria:
- Patient died before scheduled follow-up visit (March 2005)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Overall survival
Outcome Time Frame:
7 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: Commission Nationale de l'Informatique et des Libertés (CNIL)
Study ID:
ML22958
NCT ID:
NCT01332981
Start Date:
April 2010
Completion Date:
January 2011
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
